DPR & CMA Data on Pharmaceutical grade lactose and by product processing from milk

The project focuses on the production of pharmaceutical grade lactose, a widely used excipient in the pharmaceutical industry, particularly in the formulation of tablets and capsules. Derived from the milk processing industry, lactose is obtained from whey, a by-product of cheese manufacturing, which drastically enhances the economic sustainability by maximizing the utilization of dairy resources. The manufacturing process involves advanced filtration techniques, purification, and sterilization processes to ensure that the final product meets stringent pharmaceutical standards. By producing high-quality lactose, the project aims to cater to pharmaceutical companies, dietary supplement manufacturers, and various sectors of the healthcare industry. The by-products generated during lactose processing can also be harnessed for other applications, including animal feed and nutritional products, thereby contributing to circular economy practices. This project not only offers potential financial profitability but also contributes to environmental sustainability by reducing waste and promoting more efficient use of milk as a raw material. The market for lactose is growing, driven by increasing demand for lactose-based medications and the expansion of the pharmaceutical sector globally. Innovations in lactose processing techniques can enhance the quality and functionality of the produced lactose, supporting research and development in the formulation of new drugs. Overall, this project positions itself at the intersection of dairy science and pharmaceutical manufacturing, harnessing synergies between food and health sectors.

• Growing demand for lactose in pharmaceutical applications globally
• Increase in production of lactose from whey to meet pharmaceutical standards
• Rising prevalence of lactose intolerance and subsequent need for lactose-free products
• Expansion of the pharmaceutical industry in emerging markets
• Potential applications of lactose in nutraceuticals and functional foods

Total capital investment ranges from ₹1,430,000 to ₹69,300,000 depending on the scale of operation. This covers plant and machinery, civil work, pre-operative expenses, and working capital. Larger scales require proportionally higher investment but typically offer better returns.

At the larger investment scale, the expected break-even is approximately approx. 5 years at approximately 55.00% capacity utilisation. Smaller setups may reach break-even sooner due to lower fixed costs relative to the capacity.

• Milk
• Whey
• Water
• Acid or enzymes for lactose extraction
• Chemicals for purification and sterility processes

• High-quality product meeting pharmaceutical standards
• Utilization of a by-product of milk reduces waste
• Established market with diverse applications in healthcare
• Innovative processing techniques enhancing product efficiency